The PGA Tour is beefing up its antidoping policy by adding blood testing and bringing its list of banned substances in line with the World Anti-Doping Agency.
The revised policy takes effect at the start of next season, in October.
Blood testing will allow the Tour to detect any use of human growth hormone, which is on the list of banned substances but cannot be detected through urine. But the Tour still plans to use urine samples for the majority of its drug testing next season.
“Urine is the far more efficient testing method of 98 percent-plus of what we’re looking for,” said Andy Levinson, the Tour’s senior vice president for tournament administration, who oversees the antidoping policy.